GENMAB AS SP.ADR/1/10DK 1 (F:GE91) — Stock Price
GENMAB AS SP.ADR/1/10DK 1 (F:GE91) is currently trading at €23.80 EUR, up 3.48% today. Over the past 52 weeks, shares have ranged between €17.00 and €29.80. This page tracks GENMAB AS SP.ADR/1/10DK 1's live share price on the F exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see GE91 market cap overview.
GENMAB AS SP.ADR/1/10DK 1 (GE91) Stock Price Chart — Daily History & Trading Volume
The chart below tracks GENMAB AS SP.ADR/1/10DK 1's daily closing share price and trading volume on the F exchange over the past year, giving a clear view of recent price momentum and liquidity.
GENMAB AS SP.ADR/1/10DK 1 Income Statement — Revenue, Profit & Earnings by Year
GENMAB AS SP.ADR/1/10DK 1's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | €3.72 Billion | €3.12 Billion | €2.39 Billion | €2.09 Billion | €1.28 Billion |
| Cost of Revenue | €238.00 Million | €143.00 Million | €33.00 Million | €0.00 | €0.00 |
| Gross Profit | €3.48 Billion | €2.98 Billion | €2.36 Billion | €2.09 Billion | €1.28 Billion |
| Research & Development | €1.61 Billion | €1.41 Billion | €1.11 Billion | €800.53 Million | €636.50 Million |
| SG&A | €626.00 Million | €549.00 Million | €478.00 Million | €385.15 Million | €195.32 Million |
| Total Operating Expenses | €2.47 Billion | €2.11 Billion | €1.62 Billion | €1.19 Billion | €831.82 Million |
| Operating Income | €1.25 Billion | €1.01 Billion | €772.00 Million | €902.00 Million | €449.55 Million |
| EBITDA | — | — | — | — | — |
| EBIT | — | — | — | — | — |
| Interest Expense | €61.00 Million | €18.00 Million | €10.00 Million | €5.61 Million | €1.98 Million |
| Income Before Tax | €1.20 Billion | €1.33 Billion | €817.00 Million | €999.58 Million | €596.46 Million |
| Income Tax Expense | — | — | — | — | — |
| Net Income | €963.00 Million | €1.13 Billion | €631.00 Million | €784.70 Million | €450.16 Million |
GENMAB AS SP.ADR/1/10DK 1 Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes GENMAB AS SP.ADR/1/10DK 1's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | €12.87 Billion | €6.39 Billion | €5.24 Billion | €4.33 Billion | €3.75 Billion |
| Total Current Assets | €2.88 Billion | €3.89 Billion | €4.92 Billion | €4.06 Billion | €3.46 Billion |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | €0.00 | €1.57 Billion | €1.97 Billion | €1.79 Billion | €1.58 Billion |
| Net Receivables | €1.11 Billion | €923.00 Million | €733.00 Million | €822.12 Million | €512.58 Million |
| Inventory | €18.00 Million | €8.65 Million | €8.46 Million | €0.00 | — |
| Property, Plant & Equipment | — | — | — | — | — |
| Goodwill | €355.00 Million | €353.67 Million | €0.00 | — | — |
| Total Liabilities | €7.03 Billion | €1.27 Billion | €546.23 Million | €408.32 Million | €370.09 Million |
| Total Current Liabilities | €1.43 Billion | €740.55 Million | €368.80 Million | €262.38 Million | €238.71 Million |
| Long-term Debt | €5.00 Billion | — | — | — | — |
| Net Debt | €3.56 Billion | — | — | — | — |
| Total Stockholder Equity | €5.85 Billion | €5.12 Billion | €4.69 Billion | €3.93 Billion | €3.38 Billion |
| Retained Earnings | €4.10 Billion | €3.29 Billion | €2.82 Billion | €2.13 Billion | €1.53 Billion |
GENMAB AS SP.ADR/1/10DK 1 Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how GENMAB AS SP.ADR/1/10DK 1 generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | €1.19 Billion | €1.08 Billion | €1.10 Billion | €563.05 Million | €339.18 Million |
| Capital Expenditures | €55.00 Million | €42.41 Million | €55.83 Million | €45.63 Million | €38.36 Million |
| Free Cash Flow | €1.13 Billion | €1.04 Billion | €1.04 Billion | €517.42 Million | €300.82 Million |
| Investing Cash Flow | — | — | — | — | — |
| Financing Cash Flow | €4.79 Billion | €-546.77 Million | €-89.97 Million | €-113.56 Million | €-63.94 Million |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | €128.00 Million | €100.59 Million | €87.00 Million | €63.18 Million | €47.19 Million |
| Depreciation | €71.00 Million | €57.62 Million | €43.80 Million | €52.10 Million | €37.75 Million |
| Change in Cash | €332.00 Million | €-844.77 Million | €815.41 Million | €52.10 Million | €128.94 Million |
GENMAB AS SP.ADR/1/10DK 1 Earnings History — EPS Actual vs. Analyst Estimates
Track GENMAB AS SP.ADR/1/10DK 1's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Aug 06, 2026 | — | 0.35 | — |
| May 07, 2026 | — | 0.18 | — |
| Feb 17, 2026 | — | 0.42 | — |
| Nov 06, 2025 | — | 0.45 | — |
| Aug 07, 2025 | — | — | — |
| May 08, 2025 | — | — | — |
| Feb 12, 2025 | — | — | — |
| Nov 06, 2024 | — | — | — |